Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases

• 主要な著者: Tatjana Welzel (著者), Klervi Golhen (著者), Andrew Atkinson (著者), Verena Gotta (著者), David Ternant (著者), Jasmin B. Kuemmerle-Deschner (著者), Christine Michler (著者), Gilbert Koch (著者), Johannes N. van den Anker (著者), Marc Pfister (著者), Andreas Woerner (著者)
• フォーマット: 図書
• 出版事項: BMC, 2024-01-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Abstract Background In pediatric rheumatic diseases (PRD), adalimumab is dosed using fixed weight-based bands irrespective of methotrexate co-treatment, disease activity (DA) or other factors that might influence adalimumab pharmacokinetics (PK). In rheumatoid arthritis (RA) adalimumab exposure betw...